Biomarkers of immunotherapy response in patients with non-small-cell lung cancer: microbiota composition, short-chain fatty acids, and intestinal permeability

Moratiel-Pellitero, Alba ; Zapata-García, María ; Gascón-Ruiz, Marta ; Sesma, Andrea ; Quílez, Elisa ; Ramirez-Labrada, Ariel ; Martínez-Lostao, Luis (Universidad de Zaragoza) ; Domingo, María Pilar ; Esteban, Patricia ; Yubero, Alfonso ; Barbero-Herranz, Raquel ; Moreno-Blanco, Ana ; Paño, José Ramón (Universidad de Zaragoza) ; Lastra, Rodrigo ; Pardo, Julián (Universidad de Zaragoza) ; Isla, Dolores ; del Campo, Rosa ; Gálvez, Eva (Universidad de Zaragoza)

Resumen: Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain patients develop immune-related adverse events. Although the search for predictors of response to these drugs is a major field of research, these issues have yet to be resolved. It has been postulated that microbiota could play a relevant role in conditioning the response to cancer treatments; however, the human factor of intestinal permeability also needs to be considered as it is closely related to the regulation of host–microbiota interaction. In this article, we analyzed the possible relationship between the response to immune checkpoint inhibitors and the onset of immune-related adverse events, gut microbiota status, and intestinal membrane permeability. In a pioneering step, we also measured short-chain fatty acid content in feces. Although the correlation analyses failed to identify predictive biomarkers, even when all variables were integrated, our patients’ microbial gut ecosystems were rich and diverse, and the intestinal barrier’s integrity was preserved. These results add new knowledge on the composition of microbiota and its correlation with barrier permeability and short-chain fatty acids and suggest that more studies are required before these potential biomarkers can be incorporated into the clinical management of patients via immune checkpoint inhibitor treatment.

Idioma: Inglés

DOI: 10.3390/cancers16061144

Año: 2024

Publicado en: Cancers 16, 6 (2024), 1144 [15 pp.]
ISSN: 2072-6694

Factor impacto JCR: 4.4 (2024)

Categ. JCR: ONCOLOGY rank: 85 / 326 = 0.261 (2024) - Q2 - T1

Factor impacto SCIMAGO: 1.462 - Oncology (Q1) - Cancer Research (Q2)

Financiación: info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00
Financiación: info:eu-repo/grantAgreement/ES/DGA/B29-23R

Tipo y forma: Article (Published version)

Área (Departamento): Área Enfermería (Dpto. Fisiatría y Enfermería)
Área (Departamento): Área Inmunología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)